OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:33 UTC. Every row links to its source record.

TET2 tet methylcytosine dioxygenase 2

ENSG00000168769 · protein coding · Open Targets profile

Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Has a preference for 5-hydroxymethylcytosine in CpG motifs. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation. Methylation at the C5 position of cytosine bases is an epigenetic modification of the mammalian genome which plays an important role in transcriptional regulation. In addition to its role in DNA demethylation, also involved in the recruitment of the O-GlcNAc transferase OGT to CpG-rich transcription start sites of active genes, thereby promoting histone H2B GlcNAcylation by OGT. {ECO:0000269|PubMed:19483684, ECO:0000269|PubMed:21057493, ECO:0000269|PubMed:21817016, ECO:0000269|PubMed:23222540, ECO:0000269|PubMed:23353889, ECO:0000269|PubMed:24315485, ECO:0000269|PubMed:32518946}.

In 15 of 15 cancers, the evidence for TET2 comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751myelodysplastic syndromemyelodysplastic syndromemyelodysplastic syndrome: somatic 0.57myelodysplastic syndrome: germline 0.94acute myeloid leukemiaacute myeloid leukemiaacute myeloid leukemia: somatic 0.71acute myeloid leukemia: germline 0.78chronic myelomonocytic leukemiachronic myelomonocytic leukemiachronic myelomonocytic leukemia: somatic 0.61chronic myelomonocytic leukemia: germline 0.96myeloproliferative disordermyeloproliferative disordermyeloproliferative disorder: somatic 0.46myeloproliferative disorder: germline 0.85lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61lymphoid neoplasm: germline 0.97myeloid neoplasmmyeloid neoplasmmyeloid neoplasm: somatic 0.46myeloid neoplasm: germline 0.94ebv-positive nodal t- and nk-cell lymph…ebv-positive nodal t- and nk-cell lymphomaebv-positive nodal t- and nk-cell lymphoma: somatic 0.80ebv-positive nodal t- and nk-cell lymphoma: germline 0.86prostate carcinomaprostate carcinomaprostate carcinoma: somatic 0.46prostate carcinoma: germline 0.92chronic myeloid leukemiachronic myeloid leukemiachronic myeloid leukemia: somatic 0.61chronic myeloid leukemia: germline 0.71myeloid leukemiamyeloid leukemiamyeloid leukemia: germline 0.99hematopoietic and lymphoid system neopl…hematopoietic and lymphoid system neoplasmhematopoietic and lymphoid system neoplasm: germline 0.98monocytic leukemiamonocytic leukemiamonocytic leukemia: germline 0.98Common Hematopoietic NeoplasmCommon Hematopoietic NeoplasmCommon Hematopoietic Neoplasm: germline 0.97breast carcinomabreast carcinomabreast carcinoma: somatic 0.46breast carcinoma: germline 0.80hematopoietic and lymphoid cell neoplasmhematopoietic and lymphoid cell neoplasmhematopoietic and lymphoid cell neoplasm: germline 0.92

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand, High-Quality Ligand
PROTAC
UniProt Ubiquitination, Database Ubiquitination, Small Molecule Binder

gnomAD loss of function constraint: o/e 2.092099905014038 (upper bound 2.302299976348877). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of TET2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of TET2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.